Previous studies have reported significant variability in SRD5A2 protein expression in BPH samples, and 10 − 36.5% of BPH samples did not express SRD5A2 protein, corresponding to the proportion of patients resistant to ARIs 6, 8, 12. This evidence concerns the gene SRD5A2 and benign prostatic hyperplasia.